Headquartered in Columbia, S.C., DigitalDerm, Inc. was founded by leading melanoma expert James Grichnik, MD, PhD, and Sam Chesnutt to develop products advancing the science of dermatology. The company's first commercial offering, MoleMapCD® technology, was developed in conjunction with the Duke Comprehensive Cancer Center, Durham, N.C., where Dr. Grichnik is a researcher and clinician. In use for more than a decade at Duke and other medical facilities, MoleMapCD technology is the new standard of care for documenting the skin of patients at high-risk of melanoma and enhancing the ability to identify melanoma in early, more treatable stages.

Although primarily in the South East, DigitalDerm is in the process of launching MoleMapCD technology nationwide, exploring international introductions on a country-by-country basis, and developing new, functionality-enhanced releases of its technology.

This web site uses ADxMenu, by studio.aplus